{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T12:46:06Z","timestamp":1775911566684,"version":"3.50.1"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND:<\/jats:title>\n            <jats:p>Pregnant women with chronic myeloid leukemia (CML) can be treated effectively with the tyrosine-kinase inhibitor imatinib, but data regarding fetal and neonatal exposure and safety are limited.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CASE:<\/jats:title>\n            <jats:p>We present a patient with newly diagnosed CML in early pregnancy. Leukapheresis and interferon-\u03b1 were initiated in the second trimester with limited benefit. Imatinib was subsequently started at 28 weeks of gestation with complete hematologic response within 4 weeks. No significant maternal or neonatal adverse effects were noted, but imatinib and its primary active metabolite concentrated in maternal breast milk and neonatal urine.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Imatinib is effective for CML in pregnancy, but caution is warranted in light of potentially unrecognized fetal and neonatal effects.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000001972","type":"journal-article","created":{"date-parts":[[2017,4,6]],"date-time":"2017-04-06T15:37:16Z","timestamp":1491493036000},"page":"831-834","source":"Crossref","is-referenced-by-count":21,"title":["Maternal, Fetal, and Neonatal Imatinib Levels With Treatment of Chronic Myeloid Leukemia in Pregnancy"],"prefix":"10.1097","volume":"129","author":[{"given":"Richard M.","family":"Burwick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Brewer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"Druker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230711","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00006254-199602000-00023","article-title":"Cancer in pregnancy: a review of the literature. Part II","volume":"51","author":"Antonelli","year":"1996","journal-title":"Obstet Gynecol Surv"},{"key":"R2-20230711","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"R3-20230711","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"R4-20230711","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome","volume":"111","author":"Pye","year":"2008","journal-title":"Blood"},{"key":"R5-20230711","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"R7-20230711","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11845-014-1084-5","article-title":"Pregnancy outcome in chronic myeloid leukemia patients on imatinib therapy","volume":"184","author":"Mukhopadhyay","year":"2015","journal-title":"Ir J Med Sci"},{"key":"R8-20230711","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1200\/JCO.2005.04.6557","article-title":"Pregnancy among patients with chronic myeloid leukemia treated with imatinib","volume":"24","author":"Ault","year":"2006","journal-title":"J Clin Oncol"},{"key":"R9-20230711","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2350\/08-03-0435.1","article-title":"Effects of chemotherapy during pregnancy on the placenta","volume":"12","author":"Abellar","year":"2009","journal-title":"Pediatr Dev Pathol"},{"key":"R10-20230711","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.leukres.2007.11.039","article-title":"Irreversible sensorineural hearing loss due to Imatinib","volume":"32","author":"Attili","year":"2008","journal-title":"Leuk Res"},{"key":"R11-20230711","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1359\/jbmr.070719","article-title":"Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms","volume":"22","author":"O'Sullivan","year":"2007","journal-title":"J Bone Miner Res"},{"key":"R12-20230711","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/annonc\/mdv172","article-title":"Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model","volume":"26","author":"Jovelet","year":"2015","journal-title":"Ann Oncol"},{"key":"R13-20230711","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.jp.7211665","article-title":"Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk","volume":"27","author":"Russell","year":"2007","journal-title":"J Perinatol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006250-201705000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T19:19:48Z","timestamp":1689103188000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006250-201705000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000001972","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}